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We previously developed a synthetic long peptide (SLP)
vaccine against HPV16 oncoproteins that induced lesion
regression in patients with HPV16+ high-grade vulvar
intraepithelial neoplasia, correlated with strong vaccine-
prompted HPV16-specific T cell responses. In patients
with HPV16-induced metastatic cervical cancer, vaccine-
induced T cell responses were weaker and did not result
in improved clinical outcome. In a preclinical HPV16
E6/E7+ mouse tumor model we studied the efficacy of
SLP vaccination combined with chemotherapy. Mice that
received either peptide vaccination or chemotherapy
showed only temporary tumor regression. Importantly,
combined chemo-immunotherapy induced complete
tumor eradication in 75% of the mice, which was associated
with a strong tumor influx of vaccine specific tumor necro-
sis factor alpha (TNFa) and interferon gamma (IFN-g)
producing CD8+ CTLs. Tumor cells incubated with
TNFa and IFN-g, together with cisplatin, enhanced their
chemokine expression and SLP vaccine-induced CTLs
appeared to migrate earlier into the tumor beds. Combina-
tion treatment in vitro caused a decrease in proliferation of
tumor cells and TNFa-induced enhancement of cisplatin-
mediated tumor cell death, accompanied by increased
expression of pro-apoptotic molecules. SLP vaccination
together with carboplatin and paclitaxel, a standard com-
bined chemotherapy, caused marked decline in the abnor-
mally high numbers of myeloid cells in blood and tumor
in the mouse model, again associated with synergy in
tumor eradication. Hence, standard chemotherapy pro-
motes the effects of SLP vaccination by better attraction of
T cells into tumors, greater sensitivity of tumors to TNFa-
mediated apoptosis, and better expansion of T cells
through depletion of myeloid derived suppressor cells
without suppression of T cells, allowing synergy in tumor
eradication. A clinical pilot study on the composition of
blood leukocytes in late stage cervical cancer patients also
revealed high numbers of myeloid cells, associated with
low T cell responses, indicating an immunosuppressed
status. When these patients were treated with carboplatin-
paclitaxel chemotherapy their immune profile was normal-
ized to that of healthy subjects. Therefore a clinical trial
was performed in which late-stage cervical cancer patients
were treated with standard chemotherapy in combination
with HPV16 SLP vaccination. Immunomonitoring
confirmed the beneficial effect of myeloid cell depletion
associated with a robust induction of HPV16-specific
T cell responses that were sustained throughout several
cycles of chemotherapy.
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